AGIOS PHARMACEUTICALS, INC.
AGIOS PHARMACEUTICALS, INC. (AGIO): 14 pipeline candidates · 9 upcoming catalysts · ~19 mo cash runway · 33 clinical trials. Updated within the last hour.
BioSniper Score
6-factor signal · derived from public data
18.5 months
D/E 0.07 · 0% dilution
Lead: Phase 3
14 candidates
9 upcoming, next in ~531d
0 buys · 35 sells (180d)
A transparent, data-derived signal for AGIOS PHARMACEUTICALS, INC.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$2.0B
Cash
$113.6M
Quarterly Burn
$118.9M
Runway
18.5 mo
Revenue
$20.7M
Cash Runway vs Catalysts
A catalyst falls after projected cash runway — potential financing / dilution risk before it hits.
Pipeline (14 candidates)
| Drug | Phase |
|---|---|
| [13C2,15N3]-tebapivat | Phase 2 |
| [14C]-tebapivat | Phase 4 |
| AG-120 | Phase 2 |
| AG-181 | Phase 1 |
| AG-236 | Phase 1 |
| AG-348 | Phase 3 |
| AG-946 | Phase 2 |
| AG881 | Phase 1 |
| Ivosidenib | Phase 3 |
| Ivosidenib Oral Tablet | Phase 3 |
Showing 10 of 14 candidates. Sign up for full pipeline.
Upcoming Catalysts (9)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Clinical data readout — efficacy/safety results are a high-impact catalyst.
68.6% historical Phase 3 primary-endpoint success rate (n=363)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
234
Total value held
$2.14B
| Holder | Shares | Value |
|---|---|---|
| armistice capital, llc | 5,916,000 | $200.1M |
| blackrock, inc. | 5,754,957 | $194.7M |
| farallon capital management llc | 5,684,000 | $192.3M |
| vanguard capital management llc | 5,264,632 | $178.1M |
| state street corp | 3,364,879 | $113.7M |
| d. e. shaw & co., inc. | 2,681,169 | $90.7M |
| lynx1 capital management lp | 2,611,568 | $88.3M |
| vanguard portfolio management llc | 2,611,035 | $88.3M |
| bnp paribas asset management holding s.a. | 1,580,840 | $53.5M |
| susquehanna international group, llp | 1,556,353 | $52.7M |
Showing top 10 of 234 institutional holders of AGIOS PHARMACEUTICALS, INC.. Sign up for the full 13F holder list and quarter-by-quarter ownership history.
Frequently asked questions
How many drug candidates are in AGIOS PHARMACEUTICALS, INC.'s pipeline?
AGIOS PHARMACEUTICALS, INC. (AGIO) has 14 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is AGIOS PHARMACEUTICALS, INC.'s lead drug candidate?
AGIOS PHARMACEUTICALS, INC.'s most advanced tracked candidate is [13C2,15N3]-tebapivat (Phase 2) for Healthy Participants.
What is AGIOS PHARMACEUTICALS, INC.'s next catalyst?
AGIOS PHARMACEUTICALS, INC.'s next tracked catalyst is a Phase3_Topline event — "Phase 3 Topline: An Open-Label Early Access Phase 3b Study of Ivosidenib in Patients With a Pretreated Locally Advanc" — expected December 1, 2027.
What is AGIOS PHARMACEUTICALS, INC.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, AGIOS PHARMACEUTICALS, INC. has approximately 18.5 months of cash runway.
What is AGIOS PHARMACEUTICALS, INC.'s market capitalization?
AGIOS PHARMACEUTICALS, INC.'s market capitalization is approximately $2.0B.
Get the full picture on AGIOS PHARMACEUTICALS, INC.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.